NCT06563804: An ongoing trial by Servier Bio-Innovation LLC
This trial is ongoing. It must report results 3 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06563804 |
|---|---|
| Title | Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 25, 2025 |
| Completion date | Oct. 9, 2025 |
| Required reporting date | Oct. 9, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 15, 2026 |
| Days late | None |